MRA Advisory Group
INDV icon

MRA Advisory Group’s Indivior Pharmaceuticals INDV Stock Holding History

MRA Advisory Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,570
Closed -$434K – 166
2026
Q2 		$434K Buy
+10,570
New +$383K 0.16% 89

Other funds holding INDV

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

MRA Advisory Group's INDV Position: Q3 2026 in Review

MRA Advisory Group sold out of Indivior Pharmaceuticals (INDV) in Q3 2026, closing a stake of 10,570 shares — an estimated $434K sold.

MRA Advisory Group first reported a position in INDV in Q2 2026 and held it in 1 quarter. The position peaked at $434K in Q2 2026. 48 funds tracked by Wall St. Rank hold INDV as of Q3 2026.

  • MRA Advisory Group reported no remaining Indivior Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • MRA Advisory Group sold 10,570 Indivior Pharmaceuticals shares in Q3 2026, an estimated $434K.
  • MRA Advisory Group first reported a position in Indivior Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • MRA Advisory Group's Indivior Pharmaceuticals position peaked at $434K in Q2 2026.
  • 48 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2026.

Based on MRA Advisory Group's 13F filing for Q3 2026, filed 7 Oct 2026.